Clinical Trials Browser

Enrolling by invitation × Urinary Bladder Neoplasms × 90 days × Clear all

Urinary Bladder Neoplasms

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05195515 2026-03-03

CONQUER

Enrolling by invitation

2,000 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06243510 2026-01-28

CARE

Phase NA Enrolling by invitation

90 enrolled

Genitourinary

Urinary Bladder Neoplasms

Clinical Trials

VIABLE

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

CONQUER

CARE